REPLi: Identify Protease Substrates

Do you have an unidentified protease? Do you want to know its target sequence?

A Rapid Endopeptidase Profiling Library (REPLi) is a generic Fluorescent Resonance Energy Transfer (FRET) Peptide Library designed specifically to overcome common hurdles and simplify the protease profiling process. Mimotopes’ REPLi Library is available off-the-shelf and ready to use from our online catalogue.

Find out more

REPLi Requirements

An advantage of REPLi is it doesn’t require any prior knowledge of the proteases under investigation to help define the sequence of the protease cleavage site.

This peptide library comprises 3375 peptides divided into 512 distinct pools, each containing only 8 peptides so it can be rapidly deconvoluted to identify the specific sequences cleaved by your proteases.

Proteases are valuable drug targets in disease treatment, therefore fast identification of protease substrates directly from cells and tissues is invaluable.

How FRET Functions

FRET is commonly used to investigate protein interactions, including proteolysis.

In REPLi, the tripeptide core sequence is book-ended by glycine residues, with a fluorescent donor and quenching acceptor on opposite ends. When proteases cleave the peptide sequence, the quenching effect ends and the donor fluoresces.

Through real time proteolytic activity monitoring, this peptide library design provides a quantitative measure of the differences in substrate processing of low-abundant proteins, as disease markers.

Is REPLi Reliable?

Validation studies with well-characterised representative proteases from each of the four mechanistic protease classes have shown the impressively specific and sensitive capabilities of REPLi.

Results obtained from REPLi can be followed up with precise directed analysis using purified custom peptides or peptide libraries.

CONTACT US TODAY

for a peptide quote! 

☎ +61 3 9565 1111

✉ australia@mimotopes.com

☎ +1 651 603 0909

 useast@mimotopes.com

☎ +61 3 9565 1111

✉ asia@mimotopes.com

☎ +44 (0)151 556 0547

✉ europe@mimotopes.com

Contact us today

for a peptide quote! 

Australia

☎ +61 3 9565 1111

✉ australia@mimotopes.com

North and South America 

☎ +1 651 603 0909

 useast@mimotopes.com

✉ uswest@mimotopes.com

asia

☎ +61 3 9565 1111

✉ asia@mimotopes.com


UK / Europe / Africa / Middle East

☎ +44 (0)151 556 0547

✉ europe@mimotopes.com

Contact us today

 for a peptide quote! 

Australia

☎ +61 3 9565 1111

australia@mimotopes.com

North and South America 

☎ +1 651 603 0909

  ✉ useast@mimotopes.com 
  ✉ uswest@mimotopes.com

asia

☎ +61 3 9565 1111

✉ asia@mimotopes.com

UK/ Europe/ Africa/ Middle East

☎ +44 (0)151 556 0547

✉ europe@mimotopes.com

Go to article: Home | Relinking the pharma supply chainGo to article: In this issueGo to article: ContentsGo to article: Mimotopes Company Insight Go to article: MimotopesGo to article: Datwyler Company Insight Go to article: DatwylerGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: ILC Dover Go to article: ButterworthGo to article: CommentGo to article: New Chinese Breakthrough Therapy designation attracts foreign companiesGo to article: Endometrial cancer patients expected to benefit from novel advancementsGo to article: Regulatory and strategic complications of marketing an oncology drug in AsiaGo to article: The biopharma revolution: navigating complexityGo to article: TRiBECA KnowledgeGo to article: PerkinElmerGo to article: In DepthGo to article: What’s in a drug name?Go to article: Improving care for rare diseases in IndiaGo to article: Focus on the patient, not the pillGo to article: Academic-industry collaborationGo to article: Rewriting the pharma supply chain for a post-pandemic world Go to article: Developing an oral Covid-19 vaccineGo to article: The Solubility Company - Company Insight Go to article: The Solubility companyGo to article: In DataGo to article: Deals analysisGo to article: The pharma industry key listGo to article: Global markets and indicesGo to article:  Macro-economic indicatorsGo to article: Macro-economic indicators (page 2)Go to article: EventsGo to article: Next issue